Betnovate Lotion 60ml (betamethasone valerate, topical): Uses, Dosage & Side Effects

What it's for (Indications)

Betamethasone valerate, topical, is used to treat various inflammatory and pruritic skin conditions including Psoriasis, Lichen simplex, planus eczema, otitis externa, prurigo, seborrheic dermatitis, contact dermatitis, steroid-responsive dermatoses of the scalp, and severe dandruff.

Dosage Information

Type	Guideline
Standard	For application to the scalp (specifically Betamethasone Valerate Foam, 0.12%): The can must be inverted for proper dispensing. Dispense a small amount onto a saucer or other cool surface; do not dispense directly onto hands as the foam will begin to melt immediately upon contact with warm skin. Using fingers, pick up small amounts of foam and gently massage into the affected scalp area until the foam disappears. Repeat this process until the entire affected scalp area is treated. Apply twice daily, once in the morning and once at night. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Betamethasone Valerate Foam, 0.12% should not be used with occlusive dressings unless directed by a physician.

Type

Guideline

Standard

For application to the scalp (specifically Betamethasone Valerate Foam, 0.12%): The can must be inverted for proper dispensing. Dispense a small amount onto a saucer or other cool surface; do not dispense directly onto hands as the foam will begin to melt immediately upon contact with warm skin. Using fingers, pick up small amounts of foam and gently massage into the affected scalp area until the foam disappears. Repeat this process until the entire affected scalp area is treated. Apply twice daily, once in the morning and once at night. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Betamethasone Valerate Foam, 0.12% should not be used with occlusive dressings unless directed by a physician.

Safety & Warnings

Common Side Effects

Common side effects at the application site include burning, itching, stinging, irritation, redness, and dryness.
Other reported local effects include numbness of fingers, skin cracking/tightening, secondary infection, skin atrophy (skin degeneration), telangiectasia (small, widened blood vessels), striae, miliaria, folliculitis, hypopigmentation, perioral dermatitis, acne, alopecia, and allergic contact dermatitis.
Systemic effects, especially with prolonged use or application over large body areas, may include cushingoid changes (due to excess cortisol-related agents) and adrenal suppression.
Conjunctivitis has also been reported.
Rarely, malaria has been reported.

Serious Warnings

Black Box Warning: None
The effects of this medicine in pregnant and nursing females are unknown; therefore, consultation with a doctor is advised before use.
Caution is recommended in patients experiencing local irritation at the application site, visual disturbances, and in elderly individuals.
Systemic effects (overall effects in the body), such as adrenal suppression and Cushing's syndrome, may occur with prolonged use, application over large body areas, or highly absorptive sites, leading to conditions like skin atrophy.
Prolonged use should be avoided.
Do not use this medicine for treating diaper dermatoses in infants.
Avoid contact with mucous membranes and the eye area.
Occlusive dressings should not be used unless specifically directed by a physician, as they may increase the incidence of adverse reactions.
Therapy should be discontinued once control of the condition is achieved.
If no improvement is seen within 2 weeks, a reassessment of the diagnosis may be necessary.

How it Works (Mechanism of Action)

Betamethasone valerate, a potent synthetic corticosteroid, exerts its therapeutic effects primarily through its anti-inflammatory, antipruritic, and vasoconstrictive properties. Upon topical application, it penetrates the cell membrane of target cells (e.g., keratinocytes, fibroblasts, immune cells) and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This binding event induces a conformational change in the receptor-ligand complex, enabling its translocation into the cell nucleus. Within the nucleus, the activated receptor complex acts as a transcription factor, interacting with specific DNA sequences known as glucocorticoid response elements (GREs) located in the promoter regions of various target genes. This interaction either upregulates the transcription of anti-inflammatory genes or downregulates the transcription of pro-inflammatory genes. Key molecular actions include the induction of lipocortin-1 (annexin A1), an endogenous protein that inhibits phospholipase A2. By inhibiting phospholipase A2, betamethasone valerate effectively curtails the release of arachidonic acid from cell membrane phospholipids. Arachidonic acid is a crucial precursor in the biosynthesis of potent inflammatory mediators such as prostaglandins, thromboxanes, and leukotrienes (collectively known as eicosanoids). Therefore, by reducing eicosanoid synthesis, the inflammatory cascade is significantly dampened. Furthermore, betamethasone valerate suppresses the synthesis and release of various pro-inflammatory cytokines (e.g., interleukins, TNF-alpha), chemokines, and adhesion molecules, which are essential for the recruitment and activation of inflammatory cells like lymphocytes, macrophages, and neutrophils. It also stabilizes lysosomal membranes, preventing the release of hydrolytic enzymes that contribute to tissue damage and inflammation. The vasoconstrictive effect is mediated by the reduction of local blood flow and capillary permeability, which minimizes edema and the extravasation of inflammatory cells. These combined actions lead to a reduction in erythema, edema, pruritus, and overall inflammatory response observed in various dermatological conditions.